Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

Baba, Motoi; Takahashi, Masato; Yamashiro, Katsushige; Yokoo, Hideki; Fukai, Moto; Sato, Masanori; Hosoda, Mitsuchika; Kamiyama, Toshiya; Taketomi, Akinobu; Yamashita, Hiroko

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

Baba, Motoi; Takahashi, Masato; Yamashiro, Katsushige et al.

Surgery today, 2016, 46(7), 843-851

Permalink : https://hdl.handle.net/2115/66414

このアイテムのアクセス数:1,132件（2026-08-18 05:37 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
SurgToday46_843	pdf	5.83 MB	1,147

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/66414
タイトル	Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer
著者	Baba, Motoi ; Takahashi, Masato ; Yamashiro, Katsushige ; Yokoo, Hideki ; Fukai, Moto ; Sato, Masanori ; Hosoda, Mitsuchika ; Kamiyama, Toshiya ; Taketomi, Akinobu ; Yamashita, Hiroko
著者名 Baba, Motoi
著者名 Takahashi, Masato
著者名 Yamashiro, Katsushige
e-Rad_Researcher 70399947 著者名 Yokoo, Hideki
e-Rad_Researcher 60374344 著者名 Fukai, Moto
著者名 Sato, Masanori
e-Rad_Researcher 40443931 著者名 Hosoda, Mitsuchika
e-Rad_Researcher 80322816 著者名 Kamiyama, Toshiya
e-Rad_Researcher 70363364 著者名 Taketomi, Akinobu
e-Rad_Researcher 70332947 著者名 Yamashita, Hiroko
言語	英語
キーワード	NF-κB/p65
	Triple-negative breast cancer
	Prognosis
	Neoadjuvant chemotherapy
発行日	2016-07
出版者	Springer
収録物名	Surgery today
巻(号)	46(7)
ページ	843-851
抄録	Purpose: Recent studies have indicated that constitutive NF-κB activity could be involved in the proliferation of triple-negative breast cancer. Methods: NF-κB/p65 expression and the effects of the NF-κB inhibitor, (-)-DHMEQ were examined in triple-negative MDA-MB-231 breast cancer cells. Women with triple-negative breast cancer treated with neoadjuvant chemotherapy between 2002 and 2012 were retrospectively analyzed. Expression of NF-κB/p65, Bcl2 and Ki67 was examined by immunohistochemistry in pre- and post-treatment specimens, and predictive factors for neoadjuvant chemotherapy and prognosis were analyzed. Results: NF-κB/p65 was dominantly expressed in the cytoplasm in MDA-MB-231 cells. Of 34 triple-negative breast cancer patients, positive staining for NF-κB/p65 expression was detected in the nuclei of a few cells in 7 tumors before neoadjuvant chemotherapy, although expression of NF-κB/p65 in the cytoplasm was detected in almost all tumor cells of 33 tumors. Expression levels of NF-κB/p65 were not associated with response to neoaduvant chemotherapy, although expression levels of cytoplasmic NF-κB/p65 intensity were significantly decreased in post-treatment tumor samples compared with those in pretreatment samples. All patients whose tumors showed strong cytoplasmic NF-κB/p65 expression before neoadjuvant chemotherapy are currently disease-free. Conclusion: Our results suggest that strong cytoplasmic NF-κB/p65 expression could be a prognostic marker in triple-negative breast cancer.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	The final publication is available at link.springer.com
PISSN	0941-1291
関連情報	PMID 26494004
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s00595-015-1265-5